Magenta Therapeutics Inc (MGTA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jason Gardner
Employees:
80
245 FIRST STREET, 4TH FLOOR, CAMBRIDGE, MA 02142
857-201-2700

Magenta Therapeutics develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy.

Data derived from most recent annual or quarterly report
Market Cap 38.81 Million Shares Outstanding60.64 Million Avg 30-day Volume 969.577 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue0.0 Debt to Equity0.0 EBITDA-72.672 Million
Price to Book Value1.4097 Operating Margin0.0 Enterprise Value66.497 Million
Current Ratio16.634 EPS Growth0.246 Quick Ratio16.287
1 Yr BETA 0.697 52-week High/Low 2.24 / 0.32 Profit Margin0.0
Operating Cash Flow Growth7.0162 Altman Z-Score5.8365 Free Cash Flow to Firm -52.959 Million
Earnings Report2023-08-03
View SEC Filings from MGTA instead.

View recent insider trading info

Magenta Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MGTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MGTA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-12-02 by BEETHAM THOMAS W.
  • 4: filed on 2022-12-02 by MAHONEY STEPHEN F.
  • 4: filed on 2022-12-02 by DEARDORF CAREN
  • 4: filed on 2022-12-02 by GARDNER JASON
  • 4: filed on 2022-12-02 by STANTS KRISTEN
  • 4: filed on 2022-08-17 by VASCONCELLES MICHAEL
  • 3: filed on 2022-08-17 by VASCONCELLES MICHAEL
  • 4: filed on 2022-06-30 by BOOTH BRUCE
  • 4: filed on 2022-06-30 by DANIEL THOMAS O
  • 4: filed on 2022-06-30 by LAWTON ALISON FRANCES

    • Events (8k)

  • 8-K: filed on 2023-05-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-05-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2023-03-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-02:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-25:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-20:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-13:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    THIRD ROCK VENTURES IV, L.P.

    THIRD ROCK VENTURES GP IV, L.P.

    TRV GP IV, LLC

    • 10% Owner
    		 3,058,204 2023-02-07 1

    GARDNER JASON SEE REMARKS

    • Officer
    • Director
    		 944,954 2022-11-30 3

    BEETHAM THOMAS W. SEE REMARKS

    • Officer
    		 19,897 2022-11-30 3

    MAHONEY STEPHEN F. SEE REMARKS

    • Officer
    		 17,264 2022-11-30 2

    STANTS KRISTEN CHIEF PEOPLE OFFICER

    • Officer
    		 20,264 2022-11-30 3

    DEARDORF CAREN CHIEF COMMERCIAL OFFICER

    • Officer
    		 19,762 2022-11-30 3

    VASCONCELLES MICHAEL

    • Director
    		 0 2022-08-15 2

    HUMPHREY JEFFREY CHIEF MEDICAL OFFICER

    • Officer
    		 75,000 2022-08-01 1

    OLSON LISA SEE REMARKS

    • Officer
    		 100,000 2022-08-01 1

    NICHOLS DAVID WAYNE CHIEF TECHNICAL OFFICER

    • Officer
    		 75,000 2022-08-01 1

    RONNEBERG AMY L

    • Director
    		 20,000 2022-06-28 1

    BOOTH BRUCE

    • Director
    		 20,000 2022-06-28 1

    DANIEL THOMAS O

    • Director
    		 20,000 2022-06-28 1

    LAWTON ALISON FRANCES

    • Director
    		 20,000 2022-06-28 1

    ALBERS JEFFREY W.

    • Director
    		 20,000 2022-06-28 1

    SCADDEN DAVID

    • Director
    		 20,000 2022-06-28 1

    MCGEORGE ANNE

    • Director
    		 20,000 2022-06-28 1

    BORISY ALEXIS

    • Director
    		 4,100 2021-08-26 0

    BONNEY MICHAEL W

    • Director
    		 18,188 2021-06-01 0

    ATLAS VENTURE FUND X, L.P.

    • 10% Owner
    		 No longer subject to file 2021-02-11 0

    ZDRAVESKI ZORAN SEE REMARKS

    • Officer
    		 0 2021-02-11 0

    DAVIS JOHN C. JR SEE REMARKS

    • Officer
    		 0 2021-02-11 0

    DRISCOLL CINDY SEE REMARKS

    • Officer
    		 0 2020-10-01 0

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

    • SEE REMARKSSEE REMARKSSEE REMARKS
    		 1,250,000 2020-06-29 0

    BYERS BLAKE

    • Director
    		 0 2020-06-05 0

    RYAN JASON SEE REMARKS

    • Officer
    		 0 2020-02-10 0

    ISACSON CHRISTINA K. CHIEF BUSINESS OFFICER

    • Officer
    		 0 2020-02-10 0

    COOKE MICHAEL P. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 240,523 2019-12-02 0

    ATLAS VENTURE FUND X, L.P.

    ATLAS VENTURE ASSOCIATES X, L.P.

    ATLAS VENTURE ASSOCIATES X, LLC

    • 10% Owner
    		 4,117,125 2019-03-20 0

    GV 2016 GP, L.L.C.

    GV 2016 GP, L.P.

    GV 2016, L.P.

    ALPHABET INC.

    • 10% Owner
    		 No longer subject to file 2018-06-25 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 22:15:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 21:45:05 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 21:15:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 20:45:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 20:15:05 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 19:45:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 19:15:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 18:45:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 18:15:03 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 17:45:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 17:15:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 16:45:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 16:15:03 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 15:45:03 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 15:15:03 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 14:45:05 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 14:15:04 UTC -7.5293 12.5993 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 13:45:05 UTC -6.5555 11.6255 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 13:15:03 UTC -6.5555 11.6255 6500000
    MAGENTA THERAPEUTICS INC MGTA 2023-05-29 12:45:03 UTC -6.5555 11.6255 6500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund MGTA -17.0 shares, $-106.76 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund MGTA -14.0 shares, $-87.92 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments